Outcomes of robotic-assisted kidney transplantation from living donors
A Retrospective Cohort Study of Prospectively Collect the Outcomes of Recipients After Robot-assisted Kidney Transplantation
This study looks at how well robotic-assisted kidney transplants from living donors work compared to traditional surgery, especially for patients who might be overweight.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | West China Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06577805 on ClinicalTrials.gov |
What this trial studies
This observational study examines the outcomes of living donor robotic-assisted kidney transplantation (RAKT) compared to traditional open surgery. It focuses on the advancements in robotic surgery technology and its applicability to transplant patients, including those with obesity. The study aims to gather data on the effectiveness and safety of RAKT, contributing to the understanding of its benefits and potential complications. By analyzing patient outcomes, the research seeks to provide insights into the viability of robotic techniques in kidney transplantation.
Who should consider this trial
Good fit: Ideal candidates for this study are living-donor kidney transplant recipients who are receiving a standard immunosuppressive regimen.
Not a fit: Patients with active infections, multi-organ transplants, a history of malignancy, or HIV infection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the safety and effectiveness of kidney transplantation procedures for patients.
How similar studies have performed: Other studies have shown promising outcomes with robotic-assisted surgeries, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. living-donor kidney transplant recipients 2. receiving standard triad immunosuppressive regimen Exclusion Criteria: 1. active infection 2. multi-organ transplantation 3. malignancy history in the donor and recipient 4. human immunodeficiency virus infection
Where this trial is running
Chengdu, Sichuan
- West China Hospital, Sichuan University — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Tao Lin, M.D.
- Email: kidney5@163.com
- Phone: 028 85582944
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.